Core Insights - Yangzheng Xiaojie Capsule is an innovative traditional Chinese medicine developed under the guidance of traditional Chinese medicine theory, targeting the pathological mechanisms of tumors and has been approved for use in primary liver cancer treatment in China [1][2] Group 1: Product Efficacy - Yangzheng Xiaojie Capsule integrates traditional methods with modern anti-cancer drugs, demonstrating a dual action of supporting the body while eliminating pathogens, which aligns with modern cancer treatment goals [1] - Clinical studies indicate that Yangzheng Xiaojie Capsule significantly improves the quality of life for patients with advanced non-small cell lung cancer, with a clinical symptom improvement rate of 83.5% [2] - In a study on primary liver cancer, the combination of Yangzheng Xiaojie Capsule with interventional chemotherapy resulted in a total effective rate of 65.2%, significantly higher than the control group's 36.1% [2] Group 2: Research and Validation - Research led by Professor Jiang Wenguo from Cardiff University found that Yangzheng Xiaojie Capsule can significantly interfere with tumor cell invasion and metastasis by inhibiting the excessive activation of the PI3K/AKT signaling pathway [1] - The same research also indicated that the capsule inhibits the activity of focal adhesion kinase, thereby suppressing tumor angiogenesis, which contributes to tumor starvation [1] Group 3: Market Expansion - Yangzheng Xiaojie Capsule has recently been approved in Thailand, marking a significant milestone in Yiling Pharmaceutical's internationalization strategy and demonstrating the practical application of traditional Chinese medicine in the "Belt and Road" initiative [4] - Yiling Pharmaceutical has successfully registered 17 innovative traditional Chinese medicines in over 50 countries and regions worldwide, indicating strong international market recognition [4]

11月25日-26日，"第八届'一带一路'中医药发展论坛暨第三届OTC品牌大会"在杭州举行。大会由中国非 处方药物协会、"一带一路"中医药发展论坛秘书处主办，浙江省医药行业协会、上海市食品药品安全研 究会联合主办。 本届大会汇聚了专家学者、国际代表、优秀企业家、媒体代表，为中医药发展与OTC品牌建设提供可落 地的品牌促进与国际化解决方案，通过深度交流共促健康行业高质量发展。 十二届全国政协副秘书长、教科文卫体委员会副主任张秋俭致辞表示，"一带一路"中医药的发展论坛已 成功举办八届，为推动中医药高质量融入"一带一路"建设，服务全球卫生健康事业，增进世界人民福祉 作出了重要贡献。她强调，"一带一路"上的中医药发展及OTC品牌发展，需进一步聚焦"做什么、怎么 做"的问题。中医药+OTC在"一带一路"平台实现世界共享，制定国际标准是关键，核心在于保障安全、 有效，最终实现中医药智慧与OTC品牌的高质量发展，为医药健康产业的发展进一步指明方向，打开更 多发展机遇的窗口。 中国非处方药物协会会长刘沛致辞指出，中医药及OTC行业肩负高质量发展使命，医药行业应坚持创新 驱动与国际化道路，让中国品牌"立起来、走出去"。国家标准 ...

以全球健康智慧驱动医药行业高质量发展 中国非处方药物协会会长刘沛致辞表示，中医药作为中华文明的瑰宝，OTC行业作为健康服务体系的重要组成部分，肩负着推动产业高质量发展、服 务全民健康的使命。我们要以政策为导向，坚持创新驱动，走国际化发展道路，让中国品牌立起来、走出去。 中国非处方药物协会名誉会长、一心堂（002727）药业集团股份有限公司董事长阮鸿献致辞表示，作为健康中国战略的重要组成部分，零售药店在提 供全方位、全周期健康服务中发挥着关键作用，要积极拓宽国际视野，以品牌铸就国际竞争力，推动产业的国际化发展，为人民群众提供更加便捷、 高效、优质的健康服务。 全球自我保健联盟(GSCF)主席塔玛拉罗杰斯以视频形式致辞表示，在加强全球自我保健制度建设方面，中国起到非常重要的作用。在自我保健方面中 国将承担领导角色，全球自我保健联盟愿意加深合作，与中国同仁学习交流。只有合作才能够让更多的人获得健康，为公众打造更加健康的未来。 11月25日-26日，"第八届'一带一路'中医药发展论坛第三届OTC品牌大会"在杭州举行。大会由中国非处方药物协会、"一带一路"中医药发展论坛秘书处 主办，浙江省医药行业协会、上海市食品药品安 ...

南方财经 21世纪经济报道记者田静澳门报道 南方财经：实验室重组后在名称中加入"机制"二字，这是否标志着我国中医药研究的核心方向正在从传 统的"经验验证"向现代化的"机理阐释"进行战略转型？ 陈新：会的。现在推进中医药现代化、国际化和产业升级还有很多障碍，其中最大的障碍是中医药作用 机制说不清、道不明。很多人喜欢用中药治疗疾病或调理身体，但没有科学精准的方式来说明中药对身 体或疾病具体产生了什么作用，这严重妨碍了中医药的现代化、国际化和产业升级。 因此，我们想直接瞄准中医药最重要的科学方向，即中药的作用机制，尤其是免疫调节的作用机制，开 展深刻研究。比如人参用于抗肿瘤治疗，我们需要弄清楚它作用于肿瘤患者的哪些细胞或分子机制，以 及中药里哪些分子是发挥作用的物质基础。只有建立了这些科学证据，才能找到有效的质量控制方法， 实现精准的质量控制，判断中药质量是否合格，是否具有良好的临床疗效和安全性。 "中药为何有效？"这一困扰世人千年的问题，如今正迎来现代科学的集中解答。今年，澳门四所国家重 点实验室完成了重组整合。其中，原来的"中药质量全国重点实验室"重组为"中药机制与质量全国重点 实验室"。 近日，中药机制与质量 ...

以岭药业专利中药全球注册情况 "走出去"：理论先行，科技破局，让中医药惠及世界 11月22日，来自越南、泰国、中国、加拿大等国家和地区的专家学者齐聚一堂，围绕络病理论的最新科 研进展展开深入交流，共商中医药现代化与国际化发展路径。 第二十一届国际络病学大会海外论坛在越南举行 "走出去"是中医药国际化的关键起点。以岭药业深知，中医药要走向世界，理论必须先行。33年来，企 业以"科技创新，成果转化，产业发展"为核心发展战略，系统构建了络病理论体系。该体系被国医大师 路志正评价为"中医络病学发展史上的第四个里程碑"。 以岭医药研究院中医药分院副院长、络病研究部主任李红蓉博士在采访时介绍称，以岭药业从"络病证 治"到"脉络学说"再到"气络学说"，搭建完成了络病研究三大理论框架，相关专著如《络病学》《脉络 论》《气络论》已出版发行，为中医络病学学科发展奠定了坚实的理论基础，《络病学》英文版教材在 弗吉尼亚整合医学大学、加拿大安大略中医学院、新加坡中医学院等海外教育机构开课，助力国际中医 药人才培养。以岭药业在该理论指导下继承创新，创立了"理论+临床+新药+实验+循证"一体化的中医 学术创新与转化新模式。 基于坚实的络病 ...

Core Insights - The "Belt and Road" Traditional Chinese Medicine Development Forum was held in Shanghai, focusing on the cultural dissemination and innovative development of traditional Chinese medicine (TCM) in the context of the Belt and Road Initiative [1] Group 1: Policy and Development - TCM is recognized as a living heritage that contributes significantly to global health systems, emphasizing the need for high-quality development driven by policy, technology, and talent [1] - There is a push for the digital standardization of TCM to align with international standards, facilitating its integration into global health frameworks [1] Group 2: International Collaboration - The forum highlighted the importance of leveraging time-honored brands and food-medicine integration products to promote TCM globally, advocating for localized production to enhance health awareness [1] - The establishment of 30 overseas centers and multilateral mechanisms aims to incorporate TCM into more national public health systems, creating accessible health products along the Belt and Road [1] Group 3: Industry Insights - Discussions at the forum included the international development and collaboration of TCM old brands and the innovative application of the food-medicine integration concept in the modern health industry [1] - Leaders from prominent TCM enterprises shared their experiences and strategies for expanding century-old brands into international markets [1]

固生堂 2024 年收入约 800 万新币，2025 年至今保持超 100%增长， 通过并购、合作、自建积极扩展海外市场，控股 OneDox 实现中西医结 合，收购大中堂增强市场控制力，新加坡首店月收入达 16-17 万新币， 回头率超 40%。 固生堂董事长持续增持公司股份，看好公司未来发展。国内市场方面， 2024 年以利润为主导，2025 年上半年利润增长显著。无锡地区在医保 政策严格管控下收入增长超 40%，区域利润率约 26%，显示出盈利能 力。 固生堂计划 2026 年进入香港和马来西亚市场，香港通过并购增加约 20 家诊所。公司人才策略是将中国优秀人才派驻海外担任总经理，构建本 地化运营团队，力争三年内成为当地中医领域头部企业。 新加坡中医支付主要依赖自费，但正推动中医药沙盒计划，未来可能纳 入医保体系。香港医疗券可用于中医诊所，商业保险也覆盖部分。公司 预计 2026 年海外收入规模将达数亿元人民币。 Q&A 固生堂 20251117 摘要 固生堂在新加坡的并购进展和战略布局是怎样的？ 固生堂于 2025 年 10 月与新加坡数字医疗平台 OneDox 达成战略合作，并在 2025 年 11 ...

Core Viewpoint - Yiling Pharmaceutical is focusing on internationalization through innovation, brand development, and expanding its influence in traditional Chinese medicine (TCM) globally [2][5]. Group 1: Internationalization Efforts - Yiling Pharmaceutical aims to enhance the international brand influence of TCM by promoting the theory of "Luo Disease" abroad, establishing over 130 professional committees in various countries [2]. - The company has developed a new academic discipline in TCM, creating textbooks and courses in over 40 higher education institutions domestically [2]. - Yiling has received significant recognition for its innovative contributions to TCM, including six national major scientific achievement awards [2]. Group 2: Product Development and Market Expansion - The company is committed to technological innovation, having successfully developed and launched 15 innovative TCM products that address major clinical treatment gaps [2]. - Yiling's products are included in over 200 clinical diagnosis and treatment guidelines, indicating their acceptance in the medical community [2]. - The approval of "Methylphenidate Hydrochloride" for market sale is expected to enrich the company's product line, particularly in treating moderate to severe Alzheimer's disease, aligning with the growing market demand due to aging populations [5]. Group 3: Financial and Trading Information - On November 12, Yiling Pharmaceutical's stock closed at 20.01 yuan, down 2.25%, with a trading volume of 668,600 shares and a turnover of 1.345 billion yuan [1]. - The net inflow of main funds was 23.33 million yuan, indicating increased short-term interest in the stock [3][4].

Core Viewpoint - Guosheng Securities has adjusted the profit forecast for Gushengtang (02273), expecting revenue and net profit growth from 2025 to 2027, maintaining a "Buy" rating for the company [1][2]. Financial Performance - Expected revenue for 2025, 2026, and 2027 is 3.27 billion, 3.94 billion, and 4.77 billion yuan, representing year-on-year growth of 8%, 21%, and 21% respectively [1]. - Expected net profit attributable to shareholders for the same years is 415 million, 529 million, and 661 million yuan, with year-on-year growth of 35%, 27%, and 25% respectively [1]. - Adjusted net profit forecasts are 460 million, 555 million, and 671 million yuan, with growth rates of 15%, 21%, and 21% [1]. Shareholder Returns - As of November 10, the company has paid out 420 million HKD in cash for interim dividends and buybacks [2]. - The company declared an interim dividend of 0.35 HKD per share, totaling 82.61 million HKD [2]. - The company has repurchased 11.05 million shares, accounting for approximately 4.68% of total share capital, with a repurchase amount of 339 million HKD [2]. Business Expansion - Since July 2025, the company has opened four new branches in Shenzhen, Tianjin, Nanjing, and Fuzhou, enhancing its service network [3]. - The Shenzhen Tianyuan Hospital is expected to improve the synergy of offline stores in the region, while the Tianjin branch marks the company's entry into the Tianjin market [3]. - The Nanjing and Fuzhou branches are part of the company's strategy to strengthen its existing service network in these cities [3]. International Expansion - The company has formed a strategic partnership with Singapore's 1doc to establish a joint venture, with Gushengtang holding 70% and managing operations [4]. - The joint venture will create dedicated TCM treatment areas within 1doc's existing clinic network, facilitating rapid scale-up [4]. - The company aims to establish 30 clinics in Singapore by the end of 2026, leveraging a combination of self-built, acquired, and cooperative models [4].

Core Points - The article highlights the deepening health cooperation between China and Egypt through the "Silk Road Acupuncture" training program organized by Sichuan Second Traditional Chinese Medicine Hospital [1][2] - The initiative aims to promote the internationalization of traditional Chinese medicine and enhance local medical talent in Egypt [1][2] Group 1: Training and Cultural Exchange - The training program took place from October 12 to November 6, involving two physicians, Zhao Jingjing and Wang Yi, who provided systematic teaching on acupuncture, moxibustion, and cupping techniques tailored to local health needs [1] - Bilingual teaching videos and Chinese-English reference materials were prepared to facilitate understanding and application among participants [1] Group 2: Community Engagement - The program included activities at various locations such as the Chinese Consulate in Alexandria, Cairo Chinese Cultural Center, and Suez Canal University, attracting local medical practitioners, students, and traditional medicine enthusiasts [1] - Additional health consultations and free medical services were provided to Chinese expatriates and local residents through collaboration with Egyptian Chinese community organizations [1] Group 3: Future Prospects - Sichuan Province plans to further expand the reach and depth of traditional Chinese medicine overseas, aiming for more practical cooperation projects to be implemented [2]